Extra-gastrointestinal stromal tumor of the pancreas: case report and review of the literature
Open Access
- 23 April 2014
- journal article
- case report
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 105
Abstract
Primary extra-gastrointestinal stromal tumor (EGISTs) arising in the pancreas is extremely rare: only 20 cases have previously been reported in the English literature from 2000 to 2013. We reported a case of EGIST of the pancreas in a 69-year-old woman who presented with abdominal pain and with a solid, heterogeneously enhancing neoplasm in the uncinate process of the pancreas, revealed preoperatively by an abdominal computed tomography scan. A diagnosis of neuroendocrine tumor was suggested. Positron emission tomography with 68Ga-DOTATOC did not show pathological accumulation of the tracer in the pancreas. The patient underwent enucleation, under ultrasonic guidance, of the pancreatic tumor that emerged to the surface of the pancreas. Histopathology and immunohistochemical examination confirmed the final diagnosis of EGIST of the pancreas (CD117+), with one mitosis per 50 high-power fields. Although rarely, GIST can involve the pancreas as a primary site, and this tumor should be considered in the differential diagnosis of pancreatic neoplasms.Keywords
This publication has 44 references indexed in Scilit:
- Pancreaticoduodenectomy versus local resection in the treatment of gastrointestinal stromal tumors of the duodenumWorld Journal of Surgical Oncology, 2013
- Pancreatic GIST with pancreas divisumInternational Journal of Surgery Case Reports, 2013
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Duodenal GIST: a single center experienceInternational Journal of Colorectal Disease, 2012
- Primary extragastrointestinal stromal tumor arising in the pancreas: report of a caseSurgery Today, 2012
- Gastrointestinal stromal tumorsInternational Journal of Colorectal Disease, 2011
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KITPLOS ONE, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033Journal of Clinical Oncology, 2008
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002